Repositioning Candidate Details
| Candidate ID: | R0340 |
| Source ID: | DB00939 |
| Source Type: | approved; vet_approved |
| Compound Type: | small molecule |
| Compound Name: | Meclofenamic acid |
| Synonyms: | Meclofenamate; Meclofenamic acid; N-(2,6-dichloro-3-methylphenyl)anthranilic acid; N-(2,6-dichloro-m-tolyl)anthranilic acid; N-(3-methyl-2,6-dichlorophenyl)anthranilic acid |
| Molecular Formula: | C14H11Cl2NO2 |
| SMILES: | CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1 |
| Structure: |
|
| DrugBank Description: | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. |
| CAS Number: | 644-62-2 |
| Molecular Weight: | 296.149 |
| DrugBank Indication: | For the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis. |
| DrugBank Pharmacology: | Meclofenamic acid is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals. |
| DrugBank MoA: | The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamic acid was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro meclofenamic acid was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamic acid. There is no evidence that meclofenamic acid alters the course of the underlying disease. |
| Targets: | Prostaglandin G/H synthase 1 inhibitor; Prostaglandin G/H synthase 2 inhibitor; Arachidonate 5-lipoxygenase inhibitor; Potassium voltage-gated channel subfamily KQT member 2 other; Potassium voltage-gated channel subfamily KQT member 3 other |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |